Page last updated: 2024-08-21

indazoles and ledoxantrone

indazoles has been researched along with ledoxantrone in 10 studies

Research

Studies (10)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (10.00)	18.7374
1990's	3 (30.00)	18.2507
2000's	6 (60.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Besserer, JA; Fry, DW	1
Bachur, NR; Lun, L; Sun, PM; Trubey, CM	1
Ferris, AM; LoRusso, PM; Philip, PA; Shields, AF; Zalupski, MM	1
Carlson, L; Freiha, FS; Grove, W; Hofacker, J; Quinn, N; Smith, DC; Trump, DL; Woolley, PV	1
Dees, EC; Donehower, RC; Grochow, LB; Grove, WR; Rummel, S; Whitfield, LR	1
Blessing, JA; Hoffman, MA; Morgan, M	1
Abbruzzese, JL; Dakhil, SR; Ellerton, JA; Hoff, PM; Pazdur, R; Winn, RJ	1
Anderson, PM; Arndt, CA; Krailo, MD; Liu-Mares, W; Reaman, GH	1
Blessing, JA; Hoffman, MA; Nuñez, ER	1
Kraut, E; Moore, T; Philip Kuebler, J; Pritchard, J	1

Trials

8 trial(s) available for indazoles and ledoxantrone

Article	Year
Phase II study of CI-958 in colorectal cancer. Cancer chemotherapy and pharmacology, 1999, Volume: 43, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Drug Administration Schedule; Female; Humans; Indazoles; Intercalating Agents; Leukopenia; Male; Middle Aged	1999
A phase II trial of CI-958 in patients with hormone-refractory prostate cancer. Cancer chemotherapy and pharmacology, 1999, Volume: 44, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Humans; Indazoles; Male; Middle Aged; Neoplasm Staging; Patient Selection; Prostate-Specific Antigen; Prostatic Neoplasms; Tomography, X-Ray Computed; Treatment Failure	1999
A phase I and pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:10 Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; DNA; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Intercalating Agents; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Time Factors	2000
Phase II trial of CI-958 in recurrent platinum-refractory ovarian carcinoma. A Gynecologic Oncology Group Study. Gynecologic oncology, 2000, Volume: 79, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms	2000
Phase II study of intravenous CI-958 in metastatic colorectal adenocarcinoma. American journal of clinical oncology, 2000, Volume: 23, Issue:6 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Female; Humans; Indazoles; Infusions, Intravenous; Male; Middle Aged	2000
Phase I study of CI-958 in children and adolescents with recurrent solid tumors. Cancer, 2001, Mar-15, Volume: 91, Issue:6 Topics: Adolescent; Adult; Age Factors; Antineoplastic Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Humans; Hypotension; Indazoles; Infusions, Intravenous; Male; Neoplasms; Neutropenia	2001
A phase II trial of CI-958 in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. Gynecologic oncology, 2001, Volume: 81, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms	2001
Phase II study of CI-958 in patients with hormone refractory prostate carcinoma. Investigational new drugs, 2004, Volume: 22, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Drug Resistance, Neoplasm; Drugs, Investigational; Humans; Indazoles; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms	2004

Other Studies

2 other study(ies) available for indazoles and ledoxantrone

Article	Year
Biochemical pharmacology and DNA-drug interactions by Cl-958, a new antitumor intercalator derived from a series of substituted 2H-[1]benzothiopyrano[4,3,2-cd]indazoles. Molecular pharmacology, 1988, Volume: 33, Issue:1 Topics: Animals; Antineoplastic Agents; DNA; DNA Damage; DNA Repair; Free Radicals; Indazoles; Intercalating Agents; Leukemia L1210; Pyrazoles; RNA; Spectrum Analysis; Superoxides; Tumor Cells, Cultured	1988
Antihelicase action of CI-958, a new drug for prostate cancer. Cancer chemotherapy and pharmacology, 1998, Volume: 42, Issue:6 Topics: Antineoplastic Agents; Base Sequence; DNA Helicases; DNA Primers; Enzyme Inhibitors; Humans; Indazoles; Kinetics; Male; Prostatic Neoplasms	1998

Article

Year

Biochemical pharmacology and DNA-drug interactions by Cl-958, a new antitumor intercalator derived from a series of substituted 2H-[1]benzothiopyrano[4,3,2-cd]indazoles.

Molecular pharmacology, 1988, Volume: 33, Issue:1

Topics: Animals; Antineoplastic Agents; DNA; DNA Damage; DNA Repair; Free Radicals; Indazoles; Intercalating Agents; Leukemia L1210; Pyrazoles; RNA; Spectrum Analysis; Superoxides; Tumor Cells, Cultured

1988

Antihelicase action of CI-958, a new drug for prostate cancer.

Cancer chemotherapy and pharmacology, 1998, Volume: 42, Issue:6

Topics: Antineoplastic Agents; Base Sequence; DNA Helicases; DNA Primers; Enzyme Inhibitors; Humans; Indazoles; Kinetics; Male; Prostatic Neoplasms

1998